Atlas Trials

Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines

Clinical trial NCT02303002 · COMPLETED

Trial details

NCT number
NCT02303002
Sponsor
Revance Therapeutics, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Glabellar Frown Lines
Start date
2014-12-01
Primary completion
2015-12-01
Enrollment
268

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.